Galectin Therapeutics (GALT) Operating Income (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Operating Income of -$4.1 million for Q1 2026, up 48.37% year-over-year from -$2.7 million in Q1 2025, and down 21.16% quarter-over-quarter from -$3.4 million in Q4 2025.
Galectin Therapeutics (GALT) Operating Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 48.37% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$16.3 million (up 60.02% YoY), while the FY2025 annual figure was -$20.1 million, up 52.67% from the prior year.
- Operating Income for Q1 2026 stood at -$4.1 million, down from -$3.4 million in the prior quarter.
- The five-year high for Operating Income was -$3.4 million in Q4 2025, with the low at -$12.4 million in Q4 2024.
- The 5-year median for Operating Income is -$9.2 million (2023), against an average of -$8.4 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income slumped 57.27% in 2022, then jumped 72.92% in 2025.
- Galectin Therapeutics' Operating Income stood at -$10.6 million in 2022, then grew by 10.08% to -$9.6 million in 2023, then dropped by 29.99% to -$12.4 million in 2024, then surged by 72.92% to -$3.4 million in 2025, then slipped by 21.16% to -$4.1 million in 2026.
- Business Quant data shows GALT's Operating Income at -$4.1 million in Q1 2026, -$3.4 million in Q4 2025, and -$4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.08 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | -7.90 Mn |
| Dec 31, 2024 | -12.43 Mn |
| Sep 30, 2024 | -9.07 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.17 Mn |
| Jun 30, 2023 | -9.00 Mn |
| Mar 31, 2023 | -10.34 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.12 Mn |
| Jun 30, 2022 | -9.66 Mn |
| Mar 31, 2022 | -9.94 Mn |
| Dec 31, 2021 | -7.43 Mn |
| Sep 30, 2021 | -8.24 Mn |
| Jun 30, 2021 | -8.19 Mn |